Brown Rudnick LLP acted for investors in a £2,548,857 investment into F2G Ltd (the "Company") by way of a subscription for Convertible Loan Notes.

F2G is an established UK biotech focusing on the discovery and development of novel drugs to treat life threatening fungal diseases.The Company is proposing to conduct a Phase 1 study, which will evaluate the safety and pharmacokinetics of F901318 at a reduced dosing regimen. These studies are scheduled to commence in December 2017 and interim data from the 28-day cohorts is anticipated in late-March 2018. The Company anticipates that the net proceeds of the issue of the Convertible Loan Notes, together with the cash in hand and a HMRC R&D tax credit will enable the Company to reach this important value inflection point. Assuming a successful outcome, the Company is planning to commence its first in patient study (Open Label Study, Study 32) in Q1 2018 followed by the Randomized Control Study (Study 31) in Q2 2019. The first in patient study will require the Company to undertake a further equity fundraising.

The Brown Rudnick team was led by London Corporate partner Sophie McGrath and Associates Sayjel Revell and Marie Fong Sing.